Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance through endoplasmic reticulum stress signaling pathway in triple negative breast cancer cells

ABSTRACT: We investigated how gefitinib-treatment and/or IL-26 stimulation affected gene expression in HCC70 cells by DNA microarray analysis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE171641 | GEO | 2021/04/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.

Project description: Not available

| S-EPMC8139965 | biostudies-literature

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.

Project description: Not available

| S-EPMC4367710 | biostudies-literature

Microarray expression profile of long noncoding RNAs in EGFR-TKI resistance of lung adenocarcinoma

Project description:Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive to EGFR tyrosine kinase inhibitors (TKIs). Prolonged cancer treatment will induce the development of acquired resistance to EGFR TKI. To gain insight into the molecular mechanisms of EGFR-TKIs resistance, we generate EGFR-TKI-resistant HCC827-8-1 cells to be analyzed by microarray with their parental HCC827cells. gefitinib resistant HCC827-8-1 cells with three replications; gefitinib-sensitive HCC827 cells with three replications

2016-08-23 | E-GEOD-74575 | biostudies-arrayexpress

Chemotherapy plus EGFR-TKI as first-line treatment provides better survival for advanced EGFR positive lung adenocarcinoma patients: updated data and exploratory in vitro study

Project description:To probe into the potential mechanisms contributing to the strong synergistic interaction between gefitinib and pemetrexed, gene expression profiles of PC-9 cells exposed to gefitinib, pemetrexed or combined treatment were analyzed using microarray technique.

2020-03-12 | E-MTAB-8661 | biostudies-arrayexpress

IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance through endoplasmic reticulum stress signaling pathway in triple negative breast cancer cells

Project description:IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance through endoplasmic reticulum stress signaling pathway in triple negative breast cancer cells

| PRJNA720400 | ENA

Interaction of IL-26 and its novel receptor EphA3 regulates EGFR-TKI resistance in triple negative breast cancer cells

Project description:We investigated how IL-26 stimulation affected gene expression in E0771 cells by DNA microarray analysis.

2021-04-01 | GSE147804 | GEO

Activation of IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer

Project description:Previous study has demonstrated that HCC827/gef cells are resistant to gefitinib-induced aspoptosis. To investigate the regulators contributed to gefitinib resistance in lung cancer, we analyzed the gene expression profiles between HCC827 andHCC827/gef cells. Reduced IGFBP7 in TKI-resistant cells reversed resistance to EGFR-TKIs, and increased EGFR-TKI-induced apoptosis through up-regulation of BIM and activation of caspases. Suppression of IGFBP7 attenuated phosphorylation of IGF-IR and downstream AKT in TKI-resistant cells.

2019-02-07 | GSE122005 | GEO

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.

Project description: Not available

| S-EPMC6474279 | biostudies-literature

Endoplasmic Reticulum Calcium Regulates Epidermal Barrier Response and Desmosomal Structure.

Project description: Not available

| S-EPMC5070468 | biostudies-literature

Characterization of the mechansims involved in resistance to EGFR inhibitors

Project description:We generated patient cSCC-derived xenografts (cSCC-PDXs) that recapitulate the histopathologic and molecular features of parental patient samples. Response to gefitinib treatment was tested in four independent models. cSCC34-PDXs showed intrinsic resistance to gefitinib, whereas three models (cSCC10-PDXs, cSCC16-PDXs and cSCC24-PDXs) initially showed a strong response to gefitinib, but acquired resistance after long-term treatment. RNA sequencing analysis were performed in matched untreated and gefitinib-resistant cSCC-PDXs to determine mechanisms behind gefitinib resistance.

2023-01-12 | GSE143588 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data